Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 15.4% in March

Structure Therapeutics Inc. (NASDAQ:GPCR) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 3,740,000 shares, a growth of 15.4% from the March 15th total of 3,240,000 shares. Based on an average trading volume of 584,800 shares, the short-interest ratio is presently 6.4 days. Approximately 9.0% of the company’s shares are short sold.

Structure Therapeutics Trading Up 0.5 %

Shares of GPCR traded up $0.17 during mid-day trading on Tuesday, hitting $37.82. The company’s stock had a trading volume of 248,543 shares, compared to its average volume of 582,014. The company’s 50-day moving average is $41.21 and its 200-day moving average is $48.78. Structure Therapeutics has a 52-week low of $21.79 and a 52-week high of $75.02. The firm has a market capitalization of $1.76 billion and a price-to-earnings ratio of -45.57.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. As a group, sell-side analysts predict that Structure Therapeutics will post -0.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Lifesci Capital restated an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Cantor Fitzgerald assumed coverage on shares of Structure Therapeutics in a research note on Tuesday, April 9th. They issued an “overweight” rating and a $65.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $85.71.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds have recently modified their holdings of the business. TrueMark Investments LLC lifted its position in Structure Therapeutics by 13.5% during the first quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock valued at $1,281,000 after acquiring an additional 3,562 shares during the last quarter. Wellington Management Group LLP lifted its position in Structure Therapeutics by 404.0% during the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock valued at $178,216,000 after acquiring an additional 3,504,747 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Structure Therapeutics by 498.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 427,735 shares of the company’s stock valued at $17,434,000 after acquiring an additional 356,302 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in Structure Therapeutics during the fourth quarter valued at approximately $475,000. Finally, FIL Ltd lifted its position in Structure Therapeutics by 8.1% during the fourth quarter. FIL Ltd now owns 9,304 shares of the company’s stock valued at $379,000 after acquiring an additional 695 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.